- Home
- AGEN vs GDO Comparison
AGEN vs GDO Comparison
Compare AGEN & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- GDO
- Stock Information
- Founded
- AGEN 1994
- GDO 2009
- Country
- AGEN United States
- GDO United States
- Employees
- AGEN N/A
- GDO N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GDO Finance Companies
- Sector
- AGEN Health Care
- GDO Finance
- Exchange
- AGEN Nasdaq
- GDO Nasdaq
- Market Cap
- AGEN 87.7M
- GDO 86.3M
- IPO Year
- AGEN 2000
- GDO N/A
- Fundamental
- Price
- AGEN $4.28
- GDO $11.95
- Analyst Decision
- AGEN Buy
- GDO
- Analyst Count
- AGEN 2
- GDO 0
- Target Price
- AGEN $14.50
- GDO N/A
- AVG Volume (30 Days)
- AGEN 497.3K
- GDO 39.4K
- Earning Date
- AGEN 08-11-2025
- GDO 01-01-0001
- Dividend Yield
- AGEN N/A
- GDO 9.81%
- EPS Growth
- AGEN N/A
- GDO N/A
- EPS
- AGEN N/A
- GDO N/A
- Revenue
- AGEN $101,706,000.00
- GDO N/A
- Revenue This Year
- AGEN $26.25
- GDO N/A
- Revenue Next Year
- AGEN N/A
- GDO N/A
- P/E Ratio
- AGEN N/A
- GDO N/A
- Revenue Growth
- AGEN N/A
- GDO N/A
- 52 Week Low
- AGEN $1.38
- GDO $11.21
- 52 Week High
- AGEN $7.34
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- AGEN 38.46
- GDO 58.83
- Support Level
- AGEN $4.31
- GDO $11.91
- Resistance Level
- AGEN $4.70
- GDO $12.00
- Average True Range (ATR)
- AGEN 0.26
- GDO 0.09
- MACD
- AGEN -0.01
- GDO -0.01
- Stochastic Oscillator
- AGEN 17.86
- GDO 58.57
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.